CTLA4 and melanoma: A variety of inflammatory and autoimmune events, ranging from grade 1 to 4 toxicities, have been observed as a result of ICI usage; the most prevalent are the dermatologic toxicities (from grade 1 to 2 rash, pruritus, vitiligo, dermatitis to grade 3 to 4 Stevens-Johnsons syndrome and epidermal necrolysis), present in 50% of melanoma patients treated with anti-CTLA-4 and up to 40% for anti-PD-1 and anti-PD-L1.